Midatech Pharma plc Revenue 2011-2026 | MTP

Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.

Traditionally defined as follows:
Revenue = Price * Quantity of products

Revenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.^[1]

This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.

Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.

Annual Revenue Midatech Pharma plc

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-	-	381 K	699 K	578 K	343 K	674 K	1.94 M	989 K	6.92 M	1.38 M	157 K	147 K	-	-

All numbers in GBP currency

Indicator range from annual reports

Maximum	Minimum	Average
6.92 M	147 K	1.29 M

References

Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).

Revenue of other stocks in the Biotechnology industry

Issuer	Revenue	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	238 M	-	2.43 %	$ 254 M	Germany
AgeX Therapeutics AGE	130 K	-	-10.17 %	$ 12.2 K	USA
BioNTech SE BNTX	482 M	$ 95.5	-3.88 %	$ 27.2 B	Germany
I-Mab IMAB	88 M	-	-	$ 866 M	China
AlloVir ALVR	165 K	-	4.14 %	$ 49.1 M	USA
Alexion Pharmaceuticals, Inc. ALXN	6.07 B	-	-	$ 40.3 B	USA
Cerus Corporation CERS	234 M	$ 2.59	-4.78 %	$ 494 M	USA
Genfit SA GNFT	70.9 M	-	2.54 %	$ 160 B	France
EyeGate Pharmaceuticals, Inc. EYEG	12.1 K	-	-1.52 %	$ 24.7 M	USA
Cardiff Oncology CRDF	593 K	$ 1.61	-2.42 %	$ 108 M	USA
Ayala Pharmaceuticals AYLA	692 K	-	-	$ 7.46 M	Israel
AstraZeneca PLC AZN	58.7 B	-	-	$ 96.9 B	Britain
Berkeley Lights BLI	78.6 M	-	-7.31 %	$ 87 M	USA
Cue Biopharma CUE	27.5 M	$ 34.94	17.05 %	$ 3.31 B	USA
Calithera Biosciences CALA	9.75 M	-	-10.95 %	$ 876 K	USA
Advaxis ADXS	13 K	-	-9.65 %	$ 45.9 M	USA
CymaBay Therapeutics CBAY	31.1 M	-	-	$ 3.45 B	USA
ChemoCentryx CCXI	32.2 M	-	-	$ 3.74 B	USA
Editas Medicine EDIT	40.5 M	$ 3.04	1.33 %	$ 270 M	USA
Институт стволовых клеток человека ISKJ	1.08 B	-	-	-	Russia
Caladrius Biosciences CLBS	1 M	-	-16.75 %	$ 25.8 M	USA
Exelixis EXEL	2.32 B	$ 44.42	0.57 %	$ 12.1 B	USA
Aeterna Zentaris AEZS	7.5 M	-	5.93 %	$ 314 M	Canada
ACADIA Pharmaceuticals ACAD	958 M	$ 22.35	0.72 %	$ 3.7 B	USA
Aeglea BioTherapeutics AGLE	886 K	-	-	$ 1.01 B	USA
Applied Genetic Technologies Corporation AGTC	325 K	-	-	$ 26.5 M	USA
Deciphera Pharmaceuticals DCPH	163 M	-	-	$ 2.18 B	USA
AIkido Pharma AIKI	123 M	-	1.93 %	$ 17.4 M	USA
Dynavax Technologies Corporation DVAX	277 M	-	-	$ 2.02 B	USA
Galapagos NV GLPG	1.11 B	$ 28.39	-0.13 %	$ 2.69 B	Belgium
Grifols, S.A. GRFS	7.21 B	$ 8.27	0.49 %	$ 6.83 B	Spain
Can-Fite BioPharma Ltd. CANF	853 K	$ 3.5	5.42 %	$ 5.76 M	Israel
Eiger BioPharmaceuticals EIGR	15.8 M	-	-9.21 %	$ 2.55 M	USA
Eloxx Pharmaceuticals ELOX	75 K	-	-5.68 %	$ 8.28 M	USA
CureVac N.V. CVAC	48.9 M	-	-	$ 867 M	Germany
Ampio Pharmaceuticals AMPE	1.16 M	-	-11.43 %	$ 502 K	USA
ImmuCell Corporation ICCC	27.6 M	$ 8.87	1.66 %	$ 80.1 M	USA
InflaRx N.V. IFRX	29.3 K	$ 1.97	-7.51 %	$ 152 M	Germany
Applied Therapeutics APLT	9.99 M	-	-	$ 8.42 M	USA